[1]尹芝兰,肖恩华.原发性肝癌行TACE术后对乙型肝炎病毒影响[J].介入放射学杂志,2014,(12):1114-1116.
　YIN Zhi lan,XIAO En hua..The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus[J].journal interventional radiology,2014,(12):1114-1116.
点击复制

原发性肝癌行TACE术后对乙型肝炎病毒影响 ()

PDF下载中关闭

分享到：

《介入放射学杂志》[ISSN:1008-794X/CN:31-1796/R]

卷:
期数:
2014年12期
页码:
1114-1116
栏目:
综述
出版日期:
2014-12-25

文章信息/Info

Title:
The influence of TACE for primary hepatocellular carcinoma on hepatitis B virus
作者:
尹芝兰;  肖恩华
Author(s):
YIN Zhi lan;  XIAO En hua.
Department of Radiology， the Second Xiangya Hospital， Zhongnan University， Changsha， Hunan Province 410011， China
关键词:
【关键词】 肝细胞癌;  经导管动脉化疗栓塞术;  乙型肝炎病毒
文献标志码:
A
摘要:
【摘要】 原发性肝癌是我国常见的恶性肿瘤之一，具有早期症状不明显、发展速度快、预后差等特点。患者有临床症状时大多已属中、晚期，临床中，经导管动脉化疗栓塞术（TACE）是对失去手术机会的中晚期肝癌患者的首选方法之一。对乙型肝炎病毒（HBV）感染相关的原发性肝癌患者，TACE术是否能引起HBV激活，国内外学者对此的相关报道并未统一，本文就乙型肝炎相关性肝癌TACE术后对HBV激活影响的研究作一综述。

参考文献/References:

［1］ Yu SJ， Lee JH， Jang ES， et al. Hepatocellular carcinoma： high hepatitis B viral load and mortality in patients treated with transarterial chemoembolization［J］. Radiology， 2013， 267： 638 647.
［2］ Beasley RP， Hwang LY， Lin CC， et al. Hepatocellular carcinoma and hepatitis B virus. A prospective study of 22 707 men in Taiwan［J］. Lancet， 1981， 2： 1129 1133.
［3］ Chen CJ， Yang HI， Su J， et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level［J］. JAMA， 2006， 295： 65 73.
［4］ Damania P， Sen B， Dar SB， et al. Hepatitis B virus induces cell proliferation via HBx induced microRNA 21 in hepatocellular carcinoma by targeting programmed cell death protein4 （PDCD4） and phosphatase and tensin homologue （PTEN）［J］. PLoS One， 2014， 9： e91745.
［5］ Tomimaru Y， Eguchi H， Nagano H， et al. Circulating microRNA 21 as a novel biomarker for hepatocellular carcinoma［J］. J Hepatol， 2012， 56： 167 175.
［6］ Lao XM， Luo G， Ye LT， et al. Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma［J］. Liver Int， 2013， 33： 595 604.
［7］ Peng JW， Lin GN， Xiao JJ， et al. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy［J］. Asia Pac J Clin Oncol， 2012， 8： 356 361.
［8］ Park JW， Park KW， Cho SH， et al. Risk of hepatitis B exacerbation is low after transcatheter arterial chemoembolization therapy for patients with HBV related hepatocellular carcinoma： report of a prospective study［J］. Am J Gastroenterol， 2005， 100： 2194 2200.
［9］ Lao XM， Wang D， Shi M， et al. Changes in hepatitis B virus DNA levels and liver function after transcatheter arterial chemoembolization of hepatocellular carcinoma［J］. Hepatol Res， 2011， 41： 553 563.
［10］ Xu J， Wang YH， Xia JL， et al. Effect of transcatheter arterial chemoembolization on HBV DNA level in primary liver cancer patients［J］. Ai Zheng， 2009， 28： 520 523.
［11］ Yeo W， Johnson PJ. Diagnosis， prevention and management of hepatitis B virus reactivation during anticancer therapy［J］. Hepatology， 2006， 43： 209 220.
［12］ 廖 娟， 王春晖， 李 肖， 等． 经导管肝动脉化疗栓塞术对原发性肝癌患者细胞免疫及调节T细胞的影响［J］． 肝脏， 2011， 16： 198 201．
［13］ 李彩霞， 李传福， 曹 驰． 肝癌患者TACE前后细胞免疫状态变化［J］． 山东大学学报： 医学版， 2003， 41： 553 555．
［14］ 朱云杰， 蔡文辉， 张春英， 等． 拉米夫定在原发性肝癌综合性介入治疗中的应用［J］． 肝脏， 2009， 14： 346 347．
［15］ 辛桂杰， 庄树武， 蔡艳俊， 等. 抗病毒联合经导管肝动脉化疗栓塞治疗乙型肝炎后肝硬化合并肝细胞癌患者的临床观察［J］. 临床肝胆病杂志， 2012， 28： 267 269.
［16］ Peng JW， Lin GN， Xiao JJ， et al. Hepatitis B virus reactivation in hepatocellular carcinoma patients undergoing transcatheter arterial chemoembolization therapy ［J］. Asia Pac J Clin Oncol， 2012， 8： 356 361.
［17］ 江家骥， 董 菁， 叶胜龙． HBV/HCV相关性肝细胞癌抗病毒治疗专家建议［J］． 传染病信息， 2013： 76 81．

相似文献/References:

[1]姚雪松,李 槐.不可手术切除的肝细胞癌的疗效评价标准——改良ＲＥＣＩＳＴ标准更可靠[J].介入放射学杂志,2012,(03):177.
　. Ｔｈｅｒａｐｅｕｔｉｃ ｅｖａｌｕａｔｉｏｎ ｃｒｉｔｅｒｉｏｎ ｏｆ ｉｎｏｐｅｒａｂｌｅ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ： ｍｏｄｉｆｉｅｄ ＲＥＣＩＳＴ ａｓ ａ ｍｏｒｅ ｒｅｌｉａｂｌｅ ｓｔａｎｄａｒｄ[J].journal interventional radiology,2012,(12):177.
[2]梁茂全,苏洪英. 肝癌化疗栓塞前后甲胎蛋白变化模式的临床意义[J].介入放射学杂志,2012,(04):333.
　.Ｔｈｅ ｔｒａｎｓｆｏｒｍａｔｉｏｎ ｐａｔｔｅｒｎ ｏｆ ｓｅｒｕｍ аｆｅｔｏｐｒｏｔｅｉｎ ａｆｔｅｒ ｔｒａｎｓｃａｔｈｅｔｅｒ ａｒｔｅｒｉａｌ ｃｈｅｍｏｅｍｂｏｌｉｚａｔｉｏｎ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａ： ｉｔｓ ｃｌｉｎｉｃａｌ ｓｉｇｎｉｆｉｃａｎｃｅ [J].journal interventional radiology,2012,(12):333.
[3]孙 磊,施海彬,刘 圣,等.肝细胞癌肝动脉门静脉分流形成的相关因素分析[J].介入放射学杂志,2012,(03):206.
　,,et al.Ｔｈｅ ｆａｃｔｏｒｓ ｒｅｌａｔｅｄ ｔｏ ｔｈｅ ｆｏｒｍａｔｉｏｎ ｏｆ ａｒｔｅｒｉｏｐｏｒｔａｌ ｓｈｕｎｔｉｎｇ ｉｎ ｐａｔｉｅｎｔｓ ｗｉｔｈ ｈｅｐａｔｏｃｅｌｌｕｌａｒ ｃａｒｃｉｎｏｍａｓ [J].journal interventional radiology,2012,(12):206.
[4]王惠文,刘瑞宝,刘　　　岩,等.原发性肝癌ＴＡＣＥ后ＦＡＫ、ＮＦκＢｐ６５表达及意义[J].介入放射学杂志,2011,(08):621.
　WANG Hui-wen,LIU Rui-bao,LIU Yan,et al.The expression and significance of FAK and NF-κBp65 in hepatocellular carcinoma after transcatheter arterial chemoembolization[J].journal interventional radiology,2011,(12):621.
[5]沈海洋,刘瑞宝,刘 岩,等. 肝右叶前、后段原发性肝癌TACE后VEGF及CD34的表达水平 ；[J].介入放射学杂志,2012,(06):469.
　SHEN Hai- yang,LIU Rui- bao,LIU Yan,et al. The expression levels of vascular endothelial growth factor and CD34 in residual cancerous tissues of primary hepatocellular carcinoma located at anterior and posterior segments of right lobe liver after TACE[J].journal interventional radiology,2012,(12):469.
[6]李晓峰,钱国军,张 磊,等. 微波高功率条件下消融原发性肝癌的初步研究[J].介入放射学杂志,2011,(12):974.
　LI Xiao-feng,QIAN Guo-jun,ZHANG Lei,et al.Microwave ablation with high output power for the treatment of hepatocellular carcinoma: a preliminary study[J].journal interventional radiology,2011,(12):974.
[7]赵 艳,韩国宏,白 苇,等. 药物缓释微球肝动脉化疗栓塞治疗肝癌研究进展[J].介入放射学杂志,2012,(01):78.
　ZHAO Yan,HAN Guo-hong,BAI Wei,et al.Transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma: its research progress[J].journal interventional radiology,2012,(12):78.
[8]彭辽河,胡晓燕,李 杰,等. 18F-FDG PET/CT显像在肝细胞癌TACE术后残留或复发病灶检出中的应用价值[J].介入放射学杂志,2012,(08):636.
　PENG Liao- he,HU Xiao- yan,LI Jie,et al. Clinical application of 18F- FDG PET/CT imaging in detecting residual lesions or recurrence foci of hepatocellular carcinoma after TACE treatment[J].journal interventional radiology,2012,(12):636.
[9]陆小华,朱小庆,茅国新.肝细胞癌相关单核苷酸多态性的研究进展[J].介入放射学杂志,2013,(06):520.
　LU Xiao? hua,ZHU Xiao? qing,MAO Guo? xin.. Hepatocellular carcinoma?蛳 related single nucleotide polymorphisms： recent advances in research[J].journal interventional radiology,2013,(12):520.
[10]姚雪松,闫 东,曾辉英,等.TACE联合索拉非尼治疗不能手术切除肝细胞癌介入治疗间隔时间的分析[J].介入放射学杂志,2014,(09):769.
　YAO Xue song,YAN Dong,ZENG Hui ying,et al.TACE combined with sorafenib for inoperable hepatocellular carcinoma： analysis of treatment interval[J].journal interventional radiology,2014,(12):769.
[11]王以浪,王亚非,张 亮,等. 肝细胞癌患者TACE术前后血清miR- 21表达变化及临床意义[J].介入放射学杂志,2014,(05):406.
　WANG Yi- lang,WANG Ya- fei,ZHANG Liang,et al. The changes of serum miR- 21 expression level in patients with HCC before and after TACE and its clinical significance[J].journal interventional radiology,2014,(12):406.
[12]刘璐璐,邵国良,庞佩佩.磁共振弥散加权和动态增强成像评价晚期肝癌TACE术疗效研究进展 [J].介入放射学杂志,2017,(08):756.
　LIU Lulu,SHAO Guoliang,PANG Peipei.Application of diffusion- weighted and dynamic contrast- enhanced MRI in evaluating the curative effect of TACE for advanced hepatocellular carcinoma： recent progress in research[J].journal interventional radiology,2017,(12):756.
[13]中国医师协会介入医师分会.中国肝细胞癌经动脉化疗栓塞治疗（TACE）临床实践指南[J].介入放射学杂志,2018,27(12):1117.
　Chinese College of Interventionalists,Chinese Medical Doctor Association.Chinese Clinical Practice Guidelines for transarterial chemoembolization of hepatocellular carcinoma[J].journal interventional radiology,2018,27(12):1117.
[14]张 申,张 磊,仲斌演,等.“TACE抵抗/失败”——需要全面认识[J].介入放射学杂志,2020,29(08):743.
　ZHANG Shen,ZHANG Lei,ZHONG Binyan,et al.Comprehensive understanding of the concept and connotation of “TACE- failure/refractoriness”[J].journal interventional radiology,2020,29(12):743.
[15]刘 嵘,程永德,王小林,等.中国肝细胞癌TACE治疗的历史、现状和展望 ——纪念我国介入放射学奠基人林贵教授[J].介入放射学杂志,2022,31(08):743.
　LIU Rong,CHENG Yongde,WANG Xiaolin,et al.The history, status and future of transarterial chemoembolization of hepatocellular carcinoma in China: in memory of Professor Gui Lin, the founder of interventional radiology in China[J].journal interventional radiology,2022,31(12):743.
[16]夏子聪,赵 辉.改善经导管动脉化疗栓塞术疗效的临床及基础研究进展[J].介入放射学杂志,2023,32(07):705.
　XIA Zicong,ZHAO Hui..Advances in clinical and fundamental researches for improving the efficacy of transcatheter arterial chemoembolization[J].journal interventional radiology,2023,32(12):705.
[17]陆一峰,王 祁,何忠明.构建基于控制营养状况评分的列线图预测肝细胞癌TACE治疗患者预后[J].介入放射学杂志,2023,32(12):1190.
　LU Yifeng,WANG Qi,HE Zhongming..Construction of a nomogram based on controlling nutritional status score for predicting the prognosis of hepatocellular carcinoma patients after receiving TACE[J].journal interventional radiology,2023,32(12):1190.
[18]管清龙,陈海波,刘成龙,等.体素内不相干运动-弥散加权成像评价不同栓塞材料经动脉化疗栓塞治疗肝细胞癌效果及预后[J].介入放射学杂志,2024,33(02):140.
　GUAN Qinglong,CHNE Haibo,LIU Chenglong,et al.The application of IVIM-DWI in evaluating the efficacy and prognosis of TACE using different embolization materials for hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):140.
[19]隰子涵,杨永波,邵国良.MRI和临床危险因素对中晚期肝细胞癌首次D-TACE近期疗效预测价值分析[J].介入放射学杂志,2024,33(04):376.
　XI Zihan,YANG Yongbo,SHAO Guoliang..The value of MRI and clinical risk factors in predicting the short-term efficacy of initial D-TACE in patients with intermediate and advanced stage hepatocellular carcinoma[J].journal interventional radiology,2024,33(12):376.

备注/Memo

备注/Memo:
（收稿日期：２０１4-04-０7）
（本文编辑：俞瑞纲）
更新日期/Last Update: 2014-12-24